GRAIL Executive and Leadership Team

Nick Schneider, the Co-Founder & Chief Executive Officer at GRAIL, directs the overarching strategic vision for multi-cancer early detection technologies. Schneider architects the long-term roadmap for the Galleri test, ensuring alignment between clinical research and commercial scalability. By fostering partnerships with healthcare providers and oncologists, the Co-Founder & Chief Executive Officer expands the reach of blood-based screening solutions across North American markets. This leadership role involves constant collaboration with the Board to secure resources for ongoing machine-learning development. Nick Schneider maintains a focus on shifting the trajectory of cancer mortality through innovation. By prioritizing the integration of DNA analysis into standard clinical workflows, the Co-Founder & Chief Executive Officer drives the company toward a future where early detection becomes the standard of care. Schneider ensures that every operational milestone supports the mission of saving lives through proactive diagnostic intervention.

Aaron Freidin, the Chief Financial Officer & Head of Corporate Development at GRAIL, manages the fiscal health and strategic growth initiatives of the organization. Freidin oversees capital allocation, ensuring that investments in methylation analysis technology yield maximum impact for the company. As the Chief Financial Officer & Head of Corporate Development, Freidin evaluates market opportunities and potential partnerships to strengthen the competitive position of the Galleri test. This role requires rigorous oversight of financial reporting and long-term planning to support the expansion of diagnostic services. Aaron Freidin coordinates with other C-suite leaders to align budgetary priorities with the broader mission of reducing cancer mortality. By optimizing the financial structure, the Chief Financial Officer & Head of Corporate Development secures the resources necessary for sustained innovation. Freidin drives efficiency across all corporate development activities, ensuring that the company remains well-positioned to lead the diagnostics industry.

Christin Browning, the Chief of Staff, Enterprise Commercial at GRAIL, coordinates the execution of commercial strategies across the enterprise landscape. Browning manages the operational flow between internal teams and external healthcare partners to ensure the effective deployment of multi-cancer early detection solutions. As the Chief of Staff, Enterprise Commercial, Browning streamlines communication and project management to accelerate the adoption of the Galleri test among large-scale medical networks. This leadership role involves identifying bottlenecks in the commercialization process and implementing solutions that enhance market penetration. Christin Browning works closely with the executive team to translate high-level goals into actionable commercial plans. By focusing on the needs of oncologists and healthcare systems, the Chief of Staff, Enterprise Commercial ensures that the company delivers value at every touchpoint. Browning drives the operational success of commercial initiatives, ultimately supporting the broader objective of transforming cancer screening standards.

Abram Barth, the Chief Legal Officer & Secretary at GRAIL, manages the legal framework and regulatory compliance necessary for the deployment of advanced diagnostic technologies. Barth oversees intellectual property protection, ensuring that the proprietary machine-learning algorithms and methylation analysis methods remain secure. As the Chief Legal Officer & Secretary, Barth navigates the complex regulatory landscape governing healthcare diagnostics to facilitate the widespread adoption of the Galleri test. This role involves providing counsel on corporate governance and risk management to the Board and executive leadership. Abram Barth ensures that all business activities adhere to strict industry standards, protecting the integrity of the company. By mitigating legal risks, the Chief Legal Officer & Secretary enables the organization to focus on its mission of early cancer detection. Barth drives the development of robust legal strategies that support the company's growth and long-term stability in the competitive diagnostics market.